EffRx Pharmaceuticals SA

EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications. EffRx’s lead commercialized product, Binosto® for the treatment of osteoporosis, is successfully commercialized by Licensees across US, European, Asian and Middle Eastern countries. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA - www.woda-alliance.com).